P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials

• Andrea Doria,
• Diogo Jesus,
• Ana Matos,
• Carla Henriques,
• Luís Sousa Inês

Affiliations

Andrea Doria

1Department of Medicine, University of Padua, Italy

Diogo Jesus

Rheumatology Department, Centro Hospitalar de Leiria, Leiria, Portugal

Ana Matos

4Research Centre in Digital Services (CISeD), Viseu, Portugal

Carla Henriques

4Centre for Mathematics, University of Coimbra, Coimbra, Portugal

Luís Sousa Inês

7CHUC Lupus Clinic, Rheumatology Dept., Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal